Holen Sie sich die Stockscreener-App
5.99
0.84%
0.05
Schlusskurs vom Vortag:
$5.94
Offen:
$5.91
24-Stunden-Volumen:
2.10M
Relative Volume:
1.27
Marktkapitalisierung:
$484.60M
Einnahmen:
$204.89M
Nettoeinkommen (Verlust:
$-157.30M
KGV:
-2.8374
EPS:
-2.1111
Netto-Cashflow:
$-97.76M
1W Leistung:
-14.79%
1M Leistung:
-18.50%
6M Leistung:
-47.13%
1J Leistung:
-55.76%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$5.015
$7.2173
52-Wochen-Spanne:
$5.015
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
5.99 | 484.60M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2026-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-12 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Form 8K Phathom Pharmaceuticals Inc For: 26 October By Investing.com - Investing.com UK
Comments on the FDA’s VOQUEZNA docket close November 23, 2026, Phathom (PHAT) says. - Stock Titan
Phathom Pharmaceuticals Provides Update on FDA Litigation - GlobeNewswire Inc.
Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity - Investing.com
Form 8K Phathom Pharmaceuticals Inc For: 23 October By Investing.com - Investing.com Australia
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA - GlobeNewswire Inc.
Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phathom Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast on October 29 - Quiver Quantitative
Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook - Investing.com
Phathom Pharmaceuticals Highlights New Cost-Effectiveness - GlobeNewswire
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 - Yahoo! Finance Canada
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com UK
For tax withholding, Phathom (PHAT) CFO surrenders 13,485 shares at $6.78 each. - Stock Titan
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com Nigeria
BXP Director Julie Richardson Purchases 409.1 Phantom Stock Units - Kalkine Media
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Canada
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD By Investing.com - Investing.com South Africa
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD - Investing.com UK
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERD - Quiver Quantitative
Heartburn medicine taken only when symptoms strike is being tested in a new study. - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals targets gastroenterolog... - Pluang
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com Canada
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Stocktwits
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - finance.yahoo.com
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Gains 2.68% to $9.18, Nearing Resistance at $9.64OBV Trend Line - www.dars.gov.et
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup: the Session Ends Within the Reported Technical Boundaries at the CloseFibonacci Entry Signals - siam.in
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - theglobeandmail.com
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
5.91%
2.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):